The annual meeting of the American College of Neuropsychopharmacology is designed to meet the educational needs of ACNP members and invited non-member colleagues.   Current data suggests that in any given year more than 20% of the U.S. adult population suffers from a diagnosable mental disorder. Four of the ten leading causes of disability in the U.S. are psychiatric disorders, including schizophrenia, depression, bipolar disorder, and obsessive-compulsive disorder. ACNP members have been among the leaders in identifying underlying mechanisms for these disorders and developing new treatment strategies. The desired results for the meeting are that ACNP members and their invited guests learn of the latest developments in preclinical and clinical research being performed by their colleagues and world experts in order to 1)enhance understanding of the neurobiological bases of current best practice approaches, 2)enhance understanding of neurobiological and clinical science underpinnings in development of novel therapeutic strategies, particularly for treatment-resistant forms of illness, and 3)lead to improvements in study designs for proposed clinical and basic studies.